



## Expedeon AG adds CaptSure DIY ELISA to immunoassay technology product range

*Addressing a billion-dollar market with innovative technologies which remove bottlenecks in research and discovery*

**Heidelberg, Germany and Cambridge, UK, 28 May 2019** – CaptSure™ DIY ELISA will complement Expedeon AG's product offering, as the Company (Frankfurt: EXN; ISIN: DE000A1RFM03; Prime Standard) announced today. The technology was developed by TGR BioSciences, which was acquired by Expedeon in May 2018. CaptSure DIY ELISA is designed to significantly reduce time and improve flexibility and sensitivity for ELISA assay development, enhancing Expedeon's offering for the immunoassay market at a critical time in the company's growth and development.

The immunoassay market was worth approximately USD \$1.6 to \$1.7 billion in 2017 according to an industry survey.<sup>1</sup> Amongst the market segments analysed for this report, ELISA was the most widely conducted immunoassay procedure, with the majority of users focusing on immunology, molecular biology, cell biology, biochemistry and cell signalling. Expedeon has an established foothold in the immunology and biochemistry markets through its acquisition of Innova Biosciences, and existing customers within the molecular and cellular biology space. CaptSure DIY ELISA is expected to be widely adopted by both existing and new users within academic, industrial and diagnostics development market segments.

**Dr Heikki Lanckriet, CEO of Expedeon, said:** "Expedeon's mission is to challenge convention in laboratory workflows in high value application areas, simplifying and accelerating processes by developing and supplying innovative technologies. Time efficiency, cost consciousness and high reproducibility play an essential role in scientists' everyday life. CaptSure DIY ELISA empowers researchers to streamline their workflows within the immunoassay development process to expedite potentially game-changing discoveries. This is an important step for Expedeon in strengthening its reach in the immunoassay market and enabling strong organic growth."

Immunoassays are *in vitro* tests that use antigen-antibody reaction binding to detect a wide range of biological substances in blood, serum or other body fluids. Immunoassay workflows are long, costly and tedious processes, which include reagent additions, incubations, wash steps, detection, and data management. Variable results in these workflows are further driving R&D costs in both the private and public sectors. Despite this, immunoassays, such as ELISA, have become a gold standard method in research as well as in the diagnosis of infectious diseases and chronic conditions, guiding subsequent treatment decisions.

Powered by Expedeon's proprietary technologies CaptSure and Lightning-Link®, CaptSure DIY ELISA addresses the limitations traditionally associated with ELISA assays while enabling users to assay multiple samples on a single plate, realizing both time and cost savings. Moreover, researchers are

---

<sup>1</sup> <https://www.biocompare.com/Editorial-Articles/348411-Survey-Sizes-Up-Immunoassay-Market/>

able to increase throughput and improve data consistency, thereby significantly improving the efficient transfer of assays from development into high-throughput screens.

Unlike standard ELISA systems, the CaptSure DIY ELISA kit comprises a ready-to-go assay plate, pre-coated with the CaptSure antibody, which is specific for the CaptSure peptide. The Lightning-Link technology enables users to quickly and easily conjugate their capture antibody to the CaptSure peptide also supplied within the kit. Once added to the plate, the interaction between the CaptSure pair immobilizes the immune-complex to the plate.

Earlier this month, Expeleon added ELISA-ONE™ kits, which utilize the same CaptSure technology, to its product range for use in the investigation of intracellular proteins in signalling pathways. This technology provides a solution to the many of the common issues that researchers face, and brings Expeleon closer to its mission of eliminating bottlenecks in discovery processes and thereby expediting research.

**For further information, please contact:**

**Expeleon AG**

Dr. Heikki Lanckriet

CEO/CSO

Phone: +44 1223 873 364

Email: [heikki.lanckriet@expeleon.com](mailto:heikki.lanckriet@expeleon.com)

Investor website: [www.investors.expeleon.com](http://www.investors.expeleon.com)

**MC Services AG (Investor Relations and International Media Relations)**

Raimund Gabriel

Managing Partner

Phone: +49 89 210228 0

Email: [expeleon@mc-services.eu](mailto:expeleon@mc-services.eu)

**Zyme Communications (Trade and UK Media Relations)**

Katie Odgaard

Phone: +44 (0)7787 502 947

Email: [katie.odgaard@zymecommunications.com](mailto:katie.odgaard@zymecommunications.com)

**About Expeleon AG: [www.expeleon.com](http://www.expeleon.com)**

Expeleon is an enabler of exciting advances in medical science and patient care. The Company's core technologies, innovative products and services are used in research laboratories around the world, enabling scientists to push the boundaries of research and product development, and play an integral part in new diagnostic tools being brought to market. With applications spanning the entire workflows in genomics, proteomics and immunology, Expeleon's technologies both accelerate and simplify research and make new and cost-effective processes available to biopharmaceutical and diagnostic organisations alike, thereby underpinning its customers' development and commercialisation objectives. Expeleon's products are sold through a direct sales force and several distribution partners in Europe, the USA and Asia. Expeleon AG has offices in Germany, Spain, UK, USA and Singapore. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: EXN; ISIN: DE000A1RFM03).

### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These

statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of Expeleon AG may deviate greatly from the established conclusions or implied predictions contained in such statements. Expeleon does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###